| 1 |
Sung H，Ferlay J，Siegel RL，et al．Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]．CA Cancer J Clin，2021，71（3）：209-249．
|
| 2 |
Xia C，Dong X，Li H，et al．Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]．Chin Med J (Engl)，2022，135（5）：584-590．
|
| 3 |
Cook MB，Coburn SB，Lam JR，et al．Cancer incidence and mortality risks in a large US Barrett's oesophagus cohort[J]．Gut，2018，67（3）：418-529．
|
| 4 |
Morgan E，Soerjomataram I，Gavin AT，et al．International trends in oesophageal cancer survival by histological subtype between 1995 and 2014[J]．Gut，2021，70（2）：234-242．
|
| 5 |
El-Serag HB，Naik AD，Duan Z，et al．Surveillance endoscopy is associated with improved outcomes of oesophageal adenocarcinoma detected in patients with Barrett’s oesophagus[J]．Gut，2016，65（8）：1252-1260．
|
| 6 |
Sun D，Liu D，Liu Q，et al．Nivolumab induced hyperprogressive disease in advanced esophageal squamous cell carcinoma[J]．Cancer Biol Ther，2020，21（12）：1097-1104．
|
| 7 |
FDA approves pembrolizumab for advanced esophageal squamous cell cancer[EB/OL]. 2019. [cited 2021 Dec 20th].
URL
|
| 8 |
Shitara K，Özgüroğlu M，Bang YJ，et al．Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial[J]．Lancet，2018，392（10142）：123-133．
|
| 9 |
Kato K，Shah MA，Enzinger P，et al．KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer[J]．Future Oncol，2019，15（10）：1057-1066．
|
| 10 |
Huang J，Xu J，Chen Y，et al．Camrelizumab versus investigator’s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study[J]．Lancet Oncol，2020，21（6）：832-842．
|
| 11 |
Luo H，Lu J，Bai Y，et al．Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial[J]．JAMA，2021，326（10）：916-925．
|
| 12 |
Bang YJ，Ruiz EY，Van Cutsem E，et al．Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300[J]．Ann Oncol，2018，29（10）：2052-2060．
|
| 13 |
Galsky MD，Arija JáA，Bamias A，et al．Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial[J]．Lancet，2020，395（10236）：1547-1557．
|
| 14 |
Eckstein M，Cimadamore A，Hartmann A，et al．PD-L1 assessment in urothelial carcinoma: a practical approach[J]．Ann Transl Med，2019，7（22）：690．
|
| 15 |
Tsao MS，Kerr KM，Kockx M，et al．PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project[J]．J Thorac Oncol，2018，13（9）：1302-1311．
|
| 16 |
Dislich B，Stein A，Seiler CA，et al．Expression patterns of programmed death-ligand 1 in esophageal adenocarcinomas: comparison between primary tumors and metastases[J]．Cancer Immunol Immunother，2017，66（6）：777-786．
|
| 17 |
Thompson ED，Zahurak M，Murphy A，et al．Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma[J]．Gut，2017，66（5）：794-801．
|
| 18 |
Fan Y，Che X，Qu J，et al．Exosomal PD-L1 Retains Immunosuppressive Activity and is Associated with Gastric Cancer Prognosis[J]．Ann Surg Oncol，2019，26（11）：3745-3755．
|
| 19 |
Cordonnier M，Nardin C，Chanteloup G，et al．Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients[J]．J Extracell Vesicles，2020，9（1）：1710899．
|
| 20 |
FDA approves first cancer treatment for any solid tumor with a specific genetic feature[EB/OL]．2017 [cited 2017 May 23]．
URL
|
| 21 |
Dudley JC，Lin MT，Le DT，et al．Microsatellite Instability as a Biomarker for PD-1 Blockade[J]．Clin Cancer Res，2016，22（4）：813-820．
|
| 22 |
Chao J，Fuchs CS，Shitara K，et al．Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials[J]．JAMA Oncol，2021，7（6）：895-902．
|
| 23 |
Imamura Y，Toihata T，Haraguchi I，et al．Immunogenic characteristics of microsatellite instability-low esophagogastric junction adenocarcinoma based on clinicopathological, molecular, immunological and survival analyses[J]．Int J Cancer，2021，148（5）：1260-1275．
|
| 24 |
Zhao L，Qu X，Wu Z，et al．TP53 somatic mutations are associated with poor survival in non-small cell lung cancer patients who undergo immunotherapy[J]．Aging (Albany NY)，2020，12（14）：14556-14568．
|
| 25 |
Harding JJ，Nandakumar S，Armenia J，et al．Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies. Clin Cancer Res，2019，25（7）：2116-2126.
|
| 26 |
Chan TA，Yarchoan M，Jaffee E，et al．Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic[J]．Ann Oncol，2019，30（1）：44-56．
|
| 27 |
FDA approves pembrolizumab for adults and children with TMB-H solid tumors[EB/OL]．2020 [cited 2022 Jan 12th]．
URL
|
| 28 |
Yarchoan M，Albacker LA，Hopkins AC，et al．PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers[J]．JCI Insight，2019，4（6）：e126908．
|
| 29 |
de Klerk LK，Patel AK，Derks S，et al．Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival[J]．J Immunother Cancer，2021，9:：e002472．
|
| 30 |
Greally M，Chou JF，Chatila WK，et al．Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer[J]．Clin Cancer Res，2019，25（20）：6160-6169．
|
| 31 |
Shitara K，Özgüroğlu M，Bang YJ，et al．Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma[J]．Ann Oncol，2021，32（9）：1127-1136．
|
| 32 |
Gandara DR，Paul SM，Kowanetz M，et al．Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab[J]．Nat Med，2018，24（9）：1441-1448．
|
| 33 |
Wang Z，Duan J，Cai S，et al．Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel[J]．JAMA Oncol，2019，5（5）：696-702．
|
| 34 |
Yan C，Ma X，Guo Z，et al．Time-spatial analysis of T cell receptor repertoire in esophageal squamous cell carcinoma patients treated with combined radiotherapy and PD-1 blockade[J]．Oncoimmunology，2022，11（1）：2025668．
|
| 35 |
Arce Vargas F，Furness AJS，Litchfield K，et al．Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies[J]．Cancer Cell，2018，33（4）：649-663．
|
| 36 |
Gide TN，Quek C，Menzies AM，et al．Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy[J]．Cancer Cell，2019，35（2）：238-255．
|
| 37 |
Zhang W，Yan C，Gao X，et al．Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma[J]．Oncologist，2021，26（7）：e1110-e1124．
|
| 38 |
Patil NS，Nabet BY，Müller S，et al．Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer[J]．Cancer Cell，2022，40（3）：289-300．
|
| 39 |
Schlößer HA，Thelen M，Lechner A，et al．B cells in esophago-gastric adenocarcinoma are highly differentiated, organize in tertiary lymphoid structures and produce tumor-specific antibodies[J]．Oncoimmunology，2019，8（1）：e1512458．
|
| 40 |
Li C，Pan J，Jiang Y，et al．Characteristics of the Immune Cell Infiltration Landscape in Gastric Cancer to Assistant Immunotherapy[J]．Front Genet，2021，12：793628．
|
| 41 |
Liu J，Wang Y，Yuan S，et al．Construction of an Immune Cell Infiltration Score to Evaluate the Prognosis and Therapeutic Efficacy of Ovarian Cancer Patients[J]．Front Immunol，2021，12：751594．
|
| 42 |
Gopalakrishnan V，Helmink BA，Spencer CN，et al．The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy[J]．Cancer Cell，2018，33（4）：570-580．
|
| 43 |
Lv J，Guo L，Liu JJ，et al．Alteration of the esophageal microbiota in Barrett's esophagus and esophageal adenocarcinoma[J]．World J Gastroenterol，2019，25（18）：2149-2161．
|
| 44 |
Wang Y，Guo H，Gao X，et al．The Intratumor Microbiota Signatures Associate With Subtype, Tumor Stage, and Survival Status of Esophageal Carcinoma[J]．Front Oncol，2021，11：754788．
|
| 45 |
Chaput N，Lepage P，Coutzac C，et al．Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab[J]．Ann Oncol，2017，28（6）：1368-1379．
|
| 46 |
Routy B，Le Chatelier E，Derosa L，et al．Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors[J]．Science，2018，359（6371）：91-97．
|
| 47 |
Champiat S，Dercle L，Ammari S，et al．Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1[J]．Clin Cancer Res，2017，23（8）：1920-1928．
|
| 48 |
Wang W，Wu M，Liu M，et al．Hyperprogression to camrelizumab in a patient with esophageal squamous cell carcinoma harboring EGFR kinase domain duplication[J]．J Immunother Cancer，2020，8:：e000793．
|
| 49 |
Sama S，Hadfield MJ，Lopetegui Lia N，et al．Hyperprogression in PDL1 Expressive，Recurrent Gastroesophageal-junction Adenocarcinoma After Pembrolizumab[J]．Cureus，2019，11（6）：e4862．
|
| 50 |
Lu Z，Zou J，Hu Y，et al．Serological Markers Associated With Response to Immune Checkpoint Blockade in Metastatic Gastrointestinal Tract Cancer[J]．JAMA Netw Open，2019，2（7）：e197621．
|
| 51 |
Fu X，Cui G，Liu S，et al．Linc01014 regulates gefitinib resistance in oesophagus cancer via EGFR-PI3K-AKT-mTOR signalling pathway[J]．J Cell Mol Med，2020，24（2）：1670-1675．
|
| 52 |
Zhang L，Zhao D，Wang Y，et al．Focal adhesion kinase （FAK）inhibitor-defactinib suppresses the malignant progression of human esophageal squamous cell carcinoma（ESCC）cells via effective blockade of PI3K/AKT axis and downstream molecular network[J]．Mol Carcinog，2021，60（2）：113-124．
|
| 53 |
Huang RSP，Murugesan K，Montesion M，et al．Pan-cancer landscape of CD274（PD-L1）copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression[J]．J Immunother Cancer，2021，9:：e002680．
|
| 54 |
Park S，Joung JG，Min YW，et al．Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma[J]．J Immunother Cancer，2019，7（1）：128．
|
| 55 |
Wagener-Ryczek S，Schoemmel M，Kraemer M，et al．Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma[J]．Cancer Immunol Immunother，2020，69（4）：523-533．
|
| 56 |
Brown JS，Sundar R，Lopez J．Combining DNA damaging therapeutics with immunotherapy: more haste, less speed[J]．Br J Cancer，2018，118（3）：312-324．
|
| 57 |
Li C，Zhao S，Zheng Y，et al．Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma（PALACE-1）[J]．Eur J Cancer，2021，144：232-241．
|
| 58 |
Li Z，Liu J，Zhang M，et al．A phase II study of neoadjuvant immunotherapy combined with chemotherapy (camrelizumab plus albumin paclitaxel and carboplatin） in resectable thoracic esophageal squamous cell cancer（NICE study）: Interim results[J]．J Clin Oncol，2021，39（15_suppl）：4060-4060.
|
| 59 |
Provencio M，Nadal E，Insa A，et al．Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer（NADIM）：an open-label, multicentre, single-arm, phase 2 trial[J]．Lancet Oncol，2020，21（11）：1413-1422．
|
| 60 |
Forde PM，Spicer J，Lu S，et al．Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer[J]．N Engl J Med，2022，386（21）：1973-1985．
|